Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL

The Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 study reported a high complete remission (CR) rate for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients treated with imatinib-combined chemotherapy. However, the long-term treatment efficacy remains uncertain. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatta, Yoshihiro, Mizuta, Shuichi, Matsuo, Keitaro, Ohtake, Shigeki, Iwanaga, Masako, Sugiura, Isamu, Doki, Noriko, Kanamori, Heiwa, Ueda, Yasunori, Yoshida, Chikamasa, Dobashi, Nobuaki, Maeda, Tomoya, Yujiri, Toshiaki, Monma, Fumihiko, Ito, Yoshikazu, Hayakawa, Fumihiko, Takeuchi, Jin, Kiyoi, Hitoshi, Miyazaki, Yasushi, Naoe, Tomoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097750/
https://www.ncbi.nlm.nih.gov/pubmed/29694642
http://dx.doi.org/10.1007/s00277-018-3323-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097750/
https://www.ncbi.nlm.nih.gov/pubmed/29694642
http://dx.doi.org/10.1007/s00277-018-3323-8

Ejemplares similares